Reutilization of 125I-UdR during growth of a solid mammary carcinoma: implications for the 125I-UdR loss technique
Related Experiment Video
Updated: Oct 23, 2026

Radionuclide-fluorescence Reporter Gene Imaging to Track Tumor Progression in Rodent Tumor Models
Published on: March 13, 2018
R Porschen1, W Porschen, H Mühlensiepen
1Department of Internal Medicine, University of Düsseldorf, FRG.
Abstract:
Reutilization of thymidine (TdR) and 5-iodo-2'-deoxyuridine (I-UdR) released by dying tumour cells was assayed in the syngeneic adenocarcinoma EO 771 by injecting heat killed, labelled tumour cells into tumours. 3H and 125I liberation from labelled breakdown products was measured in tumours of various sizes without or with separation of tumours into viable and necrotic portions. Internal reutilization of 3H-TdR was considerably greater than that of 125I-UdR. 125I-UdR released by dying tumour cells was reutilized at about 10%. There was no significant increase in 125I-UdR reutilization during tumour growth. It is concluded that measurements of radioactivity loss by the 125I-UdR technique can result in underestimating the real cell loss depending on the amount of internal reutilization by the tumours investigated. Compared with 3H-TdR 125I-UdR is the tracer of choice for long term studies of cell loss.
More Related Videos
09:49A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy (PRRT): 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
Published on: April 24, 2020
05:49Generation of an Orthotopic Xenograft of Pancreatic Cancer Cells by Ultrasound-Guided Injection
Published on: November 1, 2021